Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta
about
Niacin for primary and secondary prevention of cardiovascular eventsEzetimibe therapy: mechanism of action and clinical updateAntagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosisHigh density lipoprotein and metabolic disease: Potential benefits of restoring its functional propertiesNiacin Alternatives for Dyslipidemia: Fool's Gold or Gold Mine? Part II: Novel Niacin MimeticsNiacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?Origin and therapy for hypertriglyceridaemia in type 2 diabetesNiacin, an old drug with a new twistRegression of atherosclerosis: insights from animal and clinical studiesThe prevention and regression of atherosclerotic plaques: emerging treatments.Niacin Therapy, HDL Cholesterol, and Cardiovascular Disease: Is the HDL Hypothesis Defunct?Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2Optimal lipid modification: the rationale for combination therapyMetabolic syndrome, inflammation and atherosclerosisDo we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patientsGPR109A and vascular inflammationThe therapeutic role of niacin in dyslipidemia managementThe Effects of Niacin on Inflammation in Patients with Non-ST Elevated Acute Coronary SyndromeNiacin stimulates adiponectin secretion through the GPR109A receptorHDL as a prognostic biomarker for coronary atherosclerosis: the role of inflammation.The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.Utility of atherosclerosis imaging in the evaluation of high-density lipoprotein-raising therapies.LDL lowering in peripheral arterial disease: are there benefits beyond reducing cardiovascular morbidity and mortality?Differential impacts of blood pressure and lipid lowering on regression of ventricular and arterial mass: the Stop Atherosclerosis in Native Diabetics Trial.Carotid intima-media thickness studies: study design and data analysis.All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT.Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.Triglycerides and HDL cholesterol: stars or second leads in diabetes?MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study.A "hot" topic in dyslipidemia management--"how to beat a flush": optimizing niacin tolerability to promote long-term treatment adherence and coronary disease prevention.Atherogenic dyslipidemia and combination pharmacotherapy in diabetes: recent clinical trials.Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial.Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia.Combination treatment of experimental stroke with Niaspan and Simvastatin, reduces axonal damage and improves functional outcomeStatins and their interactions with other lipid-modifying medications: safety issues in the elderlyThe HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?Hyperlipidemia medication management in patients admitted for a myocardial infarction.
P2860
Q24203613-44C860FB-F720-4591-A0C4-D3BCC71736A8Q24630302-B5B5BDB8-E6E0-425C-AAED-040ECE821132Q24634165-C3A26105-04A9-4CAE-8AAB-0100605928EDQ26750603-67978A7D-6382-4D24-A9CC-E6A75DB02C1FQ26765137-AACCA16E-D823-4EE2-BA9C-92A58B7287E7Q26799534-BB69445E-6773-453C-83F5-9286FDF3F81AQ26824004-447DBD8B-093B-4EB0-A872-D05FCF3CEECFQ27002774-3C724700-33E1-451C-A1DC-A8F8286DBFA3Q27028112-5A804F92-3E6B-47AD-A78A-AD426BA92BEBQ27691367-E845056D-642B-4337-83F6-58D3A81835C0Q28086787-5A1DF707-EE45-4D28-8790-5C05CDC52CA4Q28217438-A0D01FB9-0119-4E4F-B8E1-162E1BFC2CDFQ28219266-ADED319E-4306-4B69-9466-BBC3219DF40EQ28219348-7AD1824F-87C2-4C0E-A3C4-78F122F64FB0Q28222549-99667018-6EC8-4B78-BB79-FBA21D975BC0Q28244205-8F2DD341-65E4-408D-9315-48F42EBD9157Q28287747-D1339F05-5AB4-488B-BEFC-12A35A22F0F2Q28304559-AD486470-A9D4-4B97-B66E-67255C55B2CEQ28468704-BC0091AD-E71C-4406-BB96-40F5B593BED1Q28575089-021E39BC-5AF1-4C1C-9F53-0D300A1626ADQ30251918-AA8565D1-E87D-4276-A8F1-192FFCC4E133Q30380628-525265AA-53E7-4F70-B9D6-4754F12CA269Q30401532-29902572-F20A-4B26-A7E2-C2E74E977D37Q30422549-4A514251-91FA-4F29-A201-16BCD8B6A987Q30464117-C195412C-9172-4C9A-B940-B4019920223CQ30712446-24629CDB-8647-4A9C-9EF3-9D609450DB04Q31101617-AEB9B416-15C4-4405-A8A0-F55A4FF78D7DQ33537687-8A73CCC4-583F-41AC-AC51-B85BA8C68767Q33604888-A6CE0D05-3938-4D55-951B-9D5B5B6372B6Q33610637-DFFD45EE-531C-46EE-803A-001158BC9F99Q33631184-CBBDF2F2-7CCB-4F82-A6B0-CA716422D2EEQ33765072-5AA84510-4CF1-4EBC-86DC-AC9D72C13D99Q33776194-AF35615C-8DE7-4679-BC36-BACBC2DA55FDQ33776230-73784987-B726-4EF0-B502-1AF5A600132AQ33789084-496689A6-B7D0-4304-87C0-1A24DA79C891Q33802196-B3051BC6-AFD3-430B-94AF-E8DD7B613CBEQ33912735-271044F1-07E2-4E84-A02C-347660EB4FD5Q33949348-47658E17-EB58-474E-9779-16E3762BFFBCQ33993233-9127B41C-BBF9-4962-B9A7-4C1EAFA7E6D8Q34045514-D4BDA208-654B-41EC-9B6F-BF9BDAB2C0A6
P2860
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Arterial Biology for the Inves ...... tion patients treated with sta
@en
Arterial Biology for the Inves ...... tion patients treated with sta
@nl
type
label
Arterial Biology for the Inves ...... tion patients treated with sta
@en
Arterial Biology for the Inves ...... tion patients treated with sta
@nl
prefLabel
Arterial Biology for the Inves ...... tion patients treated with sta
@en
Arterial Biology for the Inves ...... tion patients treated with sta
@nl
P2093
P921
P1433
P1476
Arterial Biology for the Inves ...... tion patients treated with sta
@en
P2093
Allen J Taylor
Hyun J Lee
Jeannie K Lee
Karen A Grace
Lance E Sullenberger
P304
P356
10.1161/01.CIR.0000148955.19792.8D
P407
P577
2004-11-10T00:00:00Z